Chest discomfort is a common challenge to clinicians; conditions vary from benign to life threatening. The differential diagnosis includes and overlaps cardiovascular, respiratory, gastrointestinal, neuromusculoskeletal & psychiatric problems, all requiring careful history and thorough investigations. However, a significant number of cases remain undiagnosed despite meticulous investigations an...

OBJECTIVE This study was conducted to assess the effect of combination treatment of quinine and rabeprazole in the treatment of uncomplicated Plasmodium falciparum malaria. METHODS The study included 50 patients of uncomplicated P. falciparum malaria. Group 1 (25 patients) received quinine and placebo (Q+P) while Group 2 (25 patients) received quinine and rabeprazole (Q+R). Diagnosis was conf...

Z. Kazimierczuk3, R. Stolarskiab, and D. Shugarae a Department of Biophysics, Institute of Experimental Physics, University of Warsaw, 02-089 Warszawa b Institut für Biophysikalische Chemie, Klinikum der Universität, 6000 Frankfurt am Main 70, GFR c Institute of Biochemistry and Biophysics, Academy of Sciences, 02-532 Warszawa, Poland Z. Naturforsch. 40c, 715-720 (1985); received February 14/Ma...

A series of clinical studies on the cytochrome P450 2C19 (CYP2C19) genotype and the pharmacokinetics and pharmacodynamics of three proton pump inhibitors (PPIs), omeprazole, lansoprazole and rabeprazole, have been conducted to establish the individualized pharmacotherapy based on the CYP2C19 genotyping, and in the present study, the CYP2C19 genotype-dependency was more pronounced for omeprazole...

              Helicobacter pylori (H. pylori) is considered the main cause of gastroduodenal diseases. For eradication Helicobacter, triple therapy actively used, so-called "Gold standard", which combines antibiotics and proton pump inhibitors. Among innovative delivery systems for gastroenterological drug formulationsfoams appear...

AIMS We aimed to assess the clinical effectiveness of oral vs. intravenous (i.v.) regular-dose proton pump inhibitor (PPI) after endoscopic injection of epinephrine in patients with peptic ulcer bleeding. METHODS Peptic ulcer patients with active bleeding, nonbleeding visible vessels, or adherent clots were enrolled after successful endoscopic haemostasis achieved by epinephrine injection. Th...

Current treatment guidelines for acid-related diseases (ARDs) recommend first-line treatment with a proton pump inhibitor (PPI) to reduce gastric acid production. PPIs are indicated in the management of gastroesophageal reflux disease (reflux esophagitis, nonerosive reflux disease), peptic ulcer (gastric and duodenal ulcer, non-steroidal anti-inflammatory drug (NSAID)-associated ulcer, bleeding...